Sierra Oncology Inc (SRRA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sierra Oncology Inc (SRRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7590
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sierra Oncology Inc (Sierra Oncology), formerly ProNAi Therapeutics Inc is a clinical stage drug development company that develops and commercializes DNA damage response therapeutics for the treatment of cancer. The company’s product candidate includes SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It also develops SRA141, a small molecule inhibitor of the cell division cycle 7 kinase. Sierra Oncology offers DNA damage response services such as cellular pathways, monitoring, signalling, and repairing DNA damage. The company also provides registration and commercialization of product candidates. It operates in the US and Canada. Sierra Oncology is headquartered in Vancouver, British Columbia, Canada.

Sierra Oncology Inc (SRRA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sierra Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sierra Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 9
Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Sierra Oncology Acquires Momelotinib and Activin Receptor from Gilead Sciences 11
Venture Financing 13
ProNAi Therapeutics Raises USD1.3 Million in Venture Financing 13
ProNAi Therapeutics Raises US$59.5 Million In Series D Financing 14
ProNAi Therapeutics Raises US$12 Million In Series C Financing 16
ProNAi Therapeutics Raises US$11 Million In Venture Financing 17
ProNAi Therapeutics Raises US$4.3 Million In Venture Financing 18
ProNAi Therapeutics Raises USD0.3 Million in Venture Financing 19
Licensing Agreements 20
ProNAi Therapeutics Enters into Licensing Agreement with CRT Pioneer 20
ProNAi Therapeutics Enters into Licensing Agreement with Carna Biosciences 21
Marina Biotech Enters Into Licensing Agreement With ProNAi Therapeutics For DNAi Therapeutics 22
Equity Offering 23
Sierra Oncology Plans to Raise up to USD200 Million in Public Offering of Securities 23
Sierra Oncology Prices Public Offering of Shares for USD42.8 Million 24
Sierra Oncology Completes Public Offering of Shares for USD29.5 Million 26
ProNAi Therapeutics Raises USD158.4 Million in IPO 28
Sierra Oncology Inc – Key Competitors 30
Sierra Oncology Inc – Key Employees 31
Sierra Oncology Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Aug 09, 2018: Sierra Oncology Reports Second Quarter Results 33
May 10, 2018: Sierra Oncology Reports First Quarter Results 35
Feb 27, 2018: Sierra Oncology Reports 2017 Year End Results 36
Nov 08, 2017: Sierra Oncology Reports Third Quarter Results 38
Aug 10, 2017: Sierra Oncology Reports Second Quarter 2017 Results 40
May 09, 2017: Sierra Oncology Reports First Quarter 2017 Results 42
Mar 02, 2017: Sierra Oncology Reports 2016 Year-End Results 43
Product News 45
02/27/2018: Sierra Oncology Provides Update on SRA141 45
02/06/2018: Sierra Oncology to host program update on SRA141 on February 27th in New York 46
Other Significant Developments 47
Jan 09, 2017: ProNAi Relaunched as Sierra Oncology to Advance DDR-Based Cancer Drugs 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Sierra Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sierra Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sierra Oncology Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Sierra Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 9
Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sierra Oncology Acquires Momelotinib and Activin Receptor from Gilead Sciences 11
ProNAi Therapeutics Raises USD1.3 Million in Venture Financing 13
ProNAi Therapeutics Raises US$59.5 Million In Series D Financing 14
ProNAi Therapeutics Raises US$12 Million In Series C Financing 16
ProNAi Therapeutics Raises US$11 Million In Venture Financing 17
ProNAi Therapeutics Raises US$4.3 Million In Venture Financing 18
ProNAi Therapeutics Raises USD0.3 Million in Venture Financing 19
ProNAi Therapeutics Enters into Licensing Agreement with CRT Pioneer 20
ProNAi Therapeutics Enters into Licensing Agreement with Carna Biosciences 21
Marina Biotech Enters Into Licensing Agreement With ProNAi Therapeutics For DNAi Therapeutics 22
Sierra Oncology Plans to Raise up to USD200 Million in Public Offering of Securities 23
Sierra Oncology Prices Public Offering of Shares for USD42.8 Million 24
Sierra Oncology Completes Public Offering of Shares for USD29.5 Million 26
ProNAi Therapeutics Raises USD158.4 Million in IPO 28
Sierra Oncology Inc, Key Competitors 30
Sierra Oncology Inc, Key Employees 31
Sierra Oncology Inc, Subsidiaries 32

List of Figures
Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sierra Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sierra Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Sierra Oncology Inc (SRRA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Glen Dimplex Group:企業の戦略的SWOT分析
    Glen Dimplex Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • F. Hoffmann-La Roche Ltd (ROG):企業の財務・戦略的SWOT分析
    F. Hoffmann-La Roche Ltd (ROG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Cummins Inc (CMI)-エネルギー分野:企業M&A・提携分析
    Summary Cummins Inc. (Cummins) is a manufacturer of diesel engines and related technologies. It designs, manufactures, services and distributes engines and related component solutions. The company offers filtration, fuel systems, control systems, after treatment devices, turbochargers, air handling …
  • Reliance Capital Ltd:企業の戦略・SWOT・財務分析
    Reliance Capital Ltd - Strategy, SWOT and Corporate Finance Report Summary Reliance Capital Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • A.H.A International Co., Ltd.:企業の戦略・SWOT・財務分析
    A.H.A International Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary A.H.A International Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • BankNordik P/F:企業の戦略・SWOT・財務分析
    BankNordik P/F - Strategy, SWOT and Corporate Finance Report Summary BankNordik P/F - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • GeneNews Ltd (GEN):医療機器:M&Aディール及び事業提携情報
    Summary GeneNews Ltd (GeneNews) is a provider of molecular diagnostic products. The company develops and commercializes diagnostics and personalized medicine for cancer and other chronic diseases. Its Sentinel Principle is a novel approach to identifying biomarkers of body state using blood. GeneNew …
  • adidas AG (ADS):企業の財務・戦略的SWOT分析
    adidas AG (ADS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Seven-Eleven Japan Co., Ltd.:企業の戦略・SWOT・財務情報
    Seven-Eleven Japan Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Seven-Eleven Japan Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Kosmos Energy Ltd (KOS):企業の財務・戦略的SWOT分析
    Kosmos Energy Ltd (KOS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • FluGen Inc-製薬・医療分野:企業M&A・提携分析
    Summary FluGen Inc (FluGen) is a healthcare services provider that offers vaccine and therapies. The company discovers, develops and commercializes new methods for the prevention and treatment of influenza infections. Its product includes redeeflu that contains mutations in the M2 gene of the virus. …
  • Open Text Corporation (OTEX):企業の財務・戦略的SWOT分析
    Open Text Corporation (OTEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Sunoco LP (SUN):石油・ガス:M&Aディール及び事業提携情報
    Summary Sunoco LP (Sunoco), a master limited partnership company that sells motor fuels in retail and wholesale channels. It offers motor fuel under brands such as Sunoco, Citgo, Chevron, Conoco, Aloha, Exxon, Mahalo, Mobil, Phillips 66, Texaco, Shell, Shamrock and Valero. The company operates throu …
  • Bri-Chem Corp. (BRY):石油・ガス:M&Aディール及び事業提携情報
    Summary Bri-Chem Corp (Bri-Chem) is an oil and gas drilling fluids provider. It manufactures, blends, packs and conducts wholesale distribution of oilfield drilling, completion, stimulation and production chemical fluids. The company supplies custom blended cementing, acidizing and fracturing chemic …
  • Altor BioScience Corp-製薬・医療分野:企業M&A・提携分析
    Summary Altor BioScience Corp (Altor BioScience) is a clinical stage biopharmaceutical company that discovers, develops and commercializes immunotherapeutic products. The company’s pipeline products include ALT-801, ALT-836, and ALT-803. Its technologies are soluble t-cell antigen receptor, inhibito …
  • Superior Industries International Inc (SUP):企業の財務・戦略的SWOT分析
    Superior Industries International Inc (SUP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Cytori Therapeutics Inc (CYTX)-医療機器分野:企業M&A・提携分析
    Summary Cytori Therapeutics Inc (Cytori) is a clinical stage regenerative medicine company. It develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) for the treatment of cardiovascular disease, orthopedic conditions and gastrointestinal disorders. The company has two …
  • Merit Medical Systems Inc (MMSI)-医療機器分野:企業M&A・提携分析
    Summary Merit Medical Systems, Inc. (Merit Medical) offers a wide range of single-use medical devices for interventional and diagnostic procedures. The company’s products include inflation devices and accessories, diagnostic and therapeutic catheters, diagnostic and hydrophilic products, thrombolyti …
  • Enbridge Inc (ENB):電力:M&Aディール及び事業提携情報
    Summary Enbridge Inc (Enbridge) is an integrated energy company. It carries out natural gas gathering, processing, transmission and distribution; transportation of crude oil; and marketing of petroleum products. The company also involved in power generation and transmission and has interests in rene …
  • Genextra Spa:製薬・医療:M&Aディール及び事業提携情報
    Summary Genextra SpA (Genextra) is a therapies developing company that discovers and develops therapies for age-related and metabolic diseases. The company develops INT-747 for comb, INT- 777 for metabolic syndrome, mono therapy and diabetes, novel HDAC and HSP90 inhibitors for the treatment of canc …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆